Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.01
$0.00
$0.00
$0.01
$120K4126 shsN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$3.44
+3.9%
$11.25
$3.05
$1,650.00
$100K1.4848,419 shs416,279 shs
NEPTF
Neptune Wellness Solutions
$0.02
$0.02
$0.00
$0.12
$68K-2.622,503 shsN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
$0.21
$36KN/A26,223 shs2,000 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%+9,900.00%+9,900.00%+25.00%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
0.00%-7.77%-68.15%-54.74%-99.80%
NEPTF
Neptune Wellness Solutions
0.00%-49.83%+7.14%+200.00%+1,499,900.00%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
3.4192 of 5 stars
3.34.00.00.02.62.51.3
NEPTF
Neptune Wellness Solutions
0.0052 of 5 stars
0.01.00.00.00.00.00.0
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.50
Moderate Buy$5,000.00145,248.84% Upside
NEPTF
Neptune Wellness Solutions
2.00
HoldN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$324.58 per shareN/A
NEPTF
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
-$2.11MN/A0.00N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$24.28M-$646.16N/AN/AN/AN/A-592.28%-208.68%N/A
NEPTF
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest NRXGQ, NEPTF, ATRX, and NCNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/20/2025Q2 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$2.7456-$0.16+$2.5856-$0.16N/AN/A
6/2/2025Q1 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$2.5820-$126.00-$123.4180-$0.63N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
1.58
1.25
NEPTF
Neptune Wellness Solutions
N/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
NEPTF
Neptune Wellness Solutions
11.72%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A

Insider Ownership

CompanyInsider Ownership
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
28.20%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
NEPTF
Neptune Wellness Solutions
5.10%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
3030,00021,000Not Optionable
NEPTF
Neptune Wellness Solutions
1304.53 million4.30 millionN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
1,70012.95 millionN/ANot Optionable

Recent News About These Companies

Habib Kairouz's Net Worth
Elicera Therapeutics AB (ELIC)
LL Lucky Games publ AB (LADYLU)
Xinjiang Daqo New Energy Co Ltd (688303)
Tsukuba Bank Ltd (8338)
PEXA Group Ltd (PXA)
Kosei Securities Co Ltd (8617)
Nusatama Berkah Tbk PT (NTBK)
Olympic Group Corp (8289)
Shandong Sanyuan Biotechnology Co Ltd (301206)
Okinawa financial Group Inc (7350)
Selvas Healthcare Inc (208370)
Al-Bad Massuot Yitzhak Ltd (ALBA)
Seven Utilities and Power PCL (7UP)
Yong Pyong Resort Corp (070960)
Aksa Enerji Uretim AS (AKSEN)
MHP Hotel AG (CDZ0)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

$0.01 0.00 (0.00%)
As of 08/22/2025

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

NuCana stock logo

NuCana NASDAQ:NCNA

$3.44 +0.13 (+3.93%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$3.39 -0.05 (-1.45%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Neptune Wellness Solutions OTC:NEPTF

$0.02 0.00 (0.00%)
As of 08/22/2025

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

NephroGenex stock logo

NephroGenex OTCMKTS:NRXGQ

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.